<DOC>
	<DOCNO>NCT01772199</DOCNO>
	<brief_summary>This randomize , parallel group , placebo-controlled study design ass whether GSK239512 enhance lesion remyelination subject Relapsing Remitting Multiple Sclerosis ( RRMS ) . Subjects RRMS stable background treatment either Avonex ( Interferon-beta1a ) Copaxone ( Glatiramer Acetate ) eligible participate . Subjects randomize 1:1 ratio placebo GSK239512 , continue manage current standard care therapy ( Copaxone Avonex ) . The total treatment period 48 week , include standard 4 week titration period 44 week maintenance treatment period ( could adapt 5-week titration 43 week maintenance period , need ) . Titration dose start 10 microgram ( mcg ) increase 80 mcg ( 10 mcg first week , 20 mcg second week , 40 mcg third week , 80 mcg fourth week ) . Subjects titrate maximum tolerated dose objective titrating high dose ( 80 mcg GSK239512 ) , whenever possible , base investigator judgement tolerability . The post-treatment follow-up period minimum 2 week duration follow end treatment Week 48 early withdrawal , appropriate .</brief_summary>
	<brief_title>Study Assess Whether GSK239512 Can Remyelinate Lesions Subjects With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>18 50 year age Diagnosed relapsingremitting course multiple sclerosis define appropriate McDonald criterion time diagnosis . Diagnosis RRMS make within approximately 10 year prior screen visit ( documented year diagnosis duration disease ) , No physical manifestation form Multiple Sclerosis ( MS ) include sign progression secondary progressive MS ( SPMS ) Currently compliant stable dose regimen Avonex ( Interferon Beta1a ) Copaxone ( Glatiramer Acetate ) management MS &gt; = 1 year prior screen visit The occurrence least one follow ( within year precede screen visit AND &gt; =2 month stable treatment Avonex OR Copaxone ) : ) 1 report and/or document relapse , OR b ) 1 Gadolinium Enhanced ( GdE ) lesion MRI Currently neurologically stable , investigator 's judgment , actively experience recover recent relapse screen visit A Kurtzke Expanded Disability Status Scale ( EDSS ) score 1 4.5 ( inclusive ) screen visit . Must agree participate clinical study involve another investigational drug device throughout participation study . Noninterventional study participation allow time involvement schedule interfere compliance study opinion investigator A female subject eligible enter study ) Not pregnant nursing , b ) Of nonchildbearing potential ( i.e . woman hysterectomy , postmenopausal , define &gt; 2 year without menses [ female subject postmenopausal &lt; 2 year must confirm Follicle Stimulating Hormone estradiol level ] , ovary surgically remove current document tubal ligation ) ; , c ) Of childbearing potential agrees use acceptable method birth control , one month prior start investigational product 1 month last dose investigational product . Informed Consent : Must competent understand information give Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve Informed Consent Form ( ICF ) must sign form prior initiation study procedure MRI : Unable undergo MRI scan ( e.g . due pacemaker , severe claustrophobia , hypersensitivity contrast medium ) , Lacks adequate venous access administration Gdenhancing agent , Findings brain MRI scan indicate clinically significant brain abnormality MS ( e.g . damage associate prior traumatic brain injury ) Past Concurrent Medical Conditions : ) History severe clinically significant CNS trauma current sequela ( e.g . traumatic brain injury , spinal cord compression ) , b ) Significant concurrent , uncontrolled medical condition disease opinion investigator could ( e.g . significant psychiatric disorder , etc ) , affect subject ' safety , impair subject 's reliable participation trial , impair evaluation endpoint , necessitate use medication allow protocol , c ) History presence myelopathy due spinal cord compression disk vertebral disease chronic progressive myelopathy , ) Diagnosis type epilepsy , e ) At risk suicide , indicate : A documented history attempt suicide significant suicidal ideation 6 month precede screen visit , OR If investigator 's judgment subject risk suicide attempt base screen visit assessment , include eCSSRS , f ) Presence significant routine sleep disturbance ( severe insomnia , nocturnal wandering , confusion , disorientation , agitation , vivid dream ) negative impact quality life , judgement investigator , may increase risk tolerability issue dose escalation , g ) Presence history hallucination , judgement investigator , may increase safety risk subject , h ) Known diagnosis history consistent positive human immunodeficiency virus ( HIV ) Past Current Medications Therapies : Have treatment follow manage MS : ) Within 1 year : fingolimod ( e.g . Gilenya ) , Rebif ( interferon beta1a ) , interferon beta1b ( e.g . Betaseron ) , mycophenolate mofetil ( e.g . CellCept ) , Recently approve medication formulation indicate management MS . Consult GlaxoSmithKline ( GSK ) Medical Monitor specific question regard eligible treatment b ) Within 2 year : natalizumab ( e.g . Tysabri ) , alemtuzumab ( e.g . Campath ) , daclizumab ( e.g . Zenapax ) , rituximab ( e.g . Rituxan ) , mitoxantrone ( e.g . Novantrone ) , cladribine ( e.g . Leustatin ) , azathioprine ( e.g . Imuran ) Have use corticotropin manage relapse within 6 month prior Screen Visit . Have treatment follow unable discontinue refrain treatment specified time period able discontinue use throughout participation clinical trial : dalfampridine /fampridine ( e.g . Ampyra ) 1 month prior Screen Visit , nabiximols ( e.g . Sativex ) 1 month prior Screen Visit , amantadine ( e.g . Symmetrel ) 3 month prior Screen Visit , leflunomide ( e.g . Arava ) 1 year prior Screen Visit Have use following medication within last 30 day 5 halflives ( whichever longer ) prior screen able discontinue use throughout participation clinical trial : Any CNS stimulant ( e.g. , modafinil , dexamphetamine , methylphenidate ) , Known potent Pglycoprotein inhibitor ( e.g . itraconazole , ketoconazole , cyclosporin , loperamide , diltiazem , verapamil , spironolactone , quinidine , bepridil , quinine , carvedilol ) , Known potent inhibitor inducer CYP3A4 enzyme ( e.g. , verapamil , ketoconazole , cimetidine , rifampin , modafinil ) , CNSpenetrant antihistamine ( e.g . bromopheniramine , chlorpheniramine , clemastine , diphenhydramine , hyrdoxyzine ) , History medically significant adverse effect ( include allergic reaction hypersensitivity ) follow treatment : Histamine H3 receptor antagonist inverse agonist , Gadolinium enhance agent , Relapse medication : glucocorticoid ( e.g. , methylprednisolone ) OR A known hypersensitivity component investigational product , relapse medication , Gadolinium enhance agent . Electrocardiogram ( ECG ) show clinically significant abnormality screening . Including QT interval correct use Bazett 's Fridericia 's formula ( QTcB QTcF ) interval &gt; =450 msec &gt; =480 msec patient Bundle Branch Block . Infectious Disease Status Screening ) Subjects document record vaccination Hepatitis B ( primary secondary immunization booster ) AND positive test hepatitis B surface antigen ( HBsAg Hepatitis B Core Antibody [ IgM antiHBc ] ) , b ) Subjects serologic evidence active Hepatitis C , indicate positive Hepatitis C Virus ( HCV ) RNA test antiHCV antibody test Laboratory Values Screening : Hematology : Total white cell count &lt; 2.0 x 109/L , Neutrophils &lt; 1.0 x 109/L , Platelets &lt; 75 x 109/L ( If range , platelet count repeat exclude platelet clump ) , Haemoglobin &lt; 80 g/L . Screening clinical chemistry liver function test : Alanine aminotransferase ( ALT ) &gt; 2.0 x upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) &gt; 2.0 x ULN , Alkaline phosphatise ( ALP ) &gt; 1.5 x ULN , Bilirubin &gt; 1.5 x ULN . Documented renal insufficiency laboratory result indicative renal insufficiency ( due risk associate administration Gadolinium base contrast agent subject moderate severe kidney disease ) : Estimated Creatinine Clearance ( CockroftGault ) &lt; 60 mL/minute If know , accord investigator judgement , subject suspect able comply study protocol requirement . Contributing factor assessment investigator could , limit : job demand , substance abuse , alcoholism , drug dependency psychological disorder Prior participation clinical trial use investigational product non approve intervention : Prior use investigational drug MS condition MS within 4 week 5 halflives ( whichever longer ) prior screen . The GSK Medical Monitor consult confirm eligibility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GSK239512</keyword>
	<keyword>remyelination</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Histamine 3 Receptor Antagonist</keyword>
	<keyword>magnetization transfer ratio</keyword>
</DOC>